In terms of the efficacy of PD-1 inhibitors in renal transplant patients with graft failure and advanced cancer, 5 out of the 11 reported patients experienced tumor progression, 4 had a partial response, 1 had a complete response, and 1 had no tumor response data. The gene discussed is PDCD1; the disease is cancer.